country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-W747255

Copy Link Print Information

Cephalexin sodium

9 Cited Publications

カスタマーレビュー

Based on 9 publication(s) in Google Scholar

Cephalexin sodium is an orally active cephalosporin Antibiotic. Cephalexin sodium disrupts bacterial cell wall synthesis and inhibits the growth of susceptible Gram-positive bacteria and some Gram-negative bacteria. Cephalexin sodium induces acute renal failure when overdosed in laboratory animals. Cephalexin sodium can be used in studies related to bacterial infections.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 38932-40-0
分子式: C₁₆H₁₆N₃NaO₄S
分子量:369.37

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Cephalexin sodium 構造式

CAS 番号: 38932-40-0

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Antibiotic アイソフォーム固有の製品をすべて表示 :

体外実験

Cephalexin (30 μg per disc) sodium exhibits in vitro activity against most indole-negative Proteus sp., Escherichia coli, Salmonella sp., Shigella sp., and Paracolobactrum sp. strains, but no activity against indole-positive Proteus sp., Pseudomonas sp., or Alcaligenes sp., and partial activity against Klebsiella-Aerobacter spp. when tested via 30-μg disc assay^[3].
Cephalexin (15-30 μg per disc) sodium potently inhibits most gram-positive bacteria and Neisseria sp. in vitro, with MIC values ranging from 0.16 μg/mL (Neisseria meningitidis strain Suederlin) to 200 μg/mL (Streptococcus sp. group D strain 9960), and disc-plate zones of inhibition correlating with tube dilution sensitivity^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Cephalexin (1.15-58.2 mg/kg; p.o.; two doses at 1 and 5 hours post-infection) demonstrates potent in vivo efficacy against experimental gram-positive bacterial infections in mice, with ED₅₀ values ranging from 1.15 mg/kg to 58.2 mg/kg across tested strains^[3].
Cephalexin (<10->166 mg/kg; p.o.; two doses at 1 and 5 hours post-infection) exhibits in vivo efficacy against a range of experimental gram-negative bacterial infections in mice, with ED₅₀ values ranging from <10 mg/kg to >166 mg/kg depending on the bacterial strain^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

McAllister strain (11 to 13 g)^[3]
Dosage:

Not specified
Administration:

p.o.; two doses at 1 and 5 hours post-infection
Result:

Achieved an oral ED₅₀ of 1.15 mg/kg against penicillin-sensitive S. aureus strain 3055.
Achieved an oral ED₅₀ of 3.7 mg/kg against penicillin-resistant S. aureus strain 3074.
Achieved an oral ED₅₀ of 1.8 mg/kg against Streptococcus pyogenes strain C203.
Achieved an oral ED₅₀ of 58.2 mg/kg against Diplococcus pneumoniae Type I.

Animal Model:

McAllister strain (11 to 13 g)^[3]
Dosage:

Not specified
Administration:

p.o.; two doses at 1 and 5 hours post-infection
Result:

Achieved an oral ED₅₀ of 22.1 mg/kg against indole-negative Proteus sp. strain PR-4.
Achieved oral ED₅₀ values >166 mg/kg against indole-positive Proteus sp. strains PR-9 and PR-15.
Achieved an oral ED₅₀ of 18.9 mg/kg against Salmonella typhosa strain SA-12.
Achieved an oral ED₅₀ of <10 mg/kg against Shigella flexneri 2b strain SH-3.
Achieved an oral ED₅₀ of 5.2 mg/kg against Klebsiella-Aerobacter spp. strain KA-14.
Achieved an oral ED₅₀ of 166 mg/kg against Klebsiella-Aerobacter spp. strain KA-17.
Achieved an oral ED₅₀ of 11.7 mg/kg against Escherichia coli strain EC-14.
Achieved an oral ED₅₀ >166 mg/kg against Escherichia coli strain EC-17.
Achieved an oral ED₅₀ <10 mg/kg against Escherichia coli strain EC-38.

化学情報

CAS 番号 38932-40-0
分子量 369.37
分子式 C₁₆H₁₆N₃NaO₄S
SMILES

O=C1N2[C@@](SCC(C)=C2C(O[Na])=O)([H])[C@@H]1NC([C@@H](C3=CC=CC=C3)N)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (9)

All

Sort by:

Journal Impact Factor

Theranostics

Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents. [Abstract]

2022 Jan 1;12(3):1187-1203. PMID: 35154482
J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
J Med Chem

Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. [Abstract]

2021 Oct 14;64(19):14344-14357. PMID: 34547896
Infect Immun

Identification and Characterization of the Neisseria gonorrhoeae MscS-Like Mechanosensitive Channel. [Abstract]

2018 May 22;86(6):e00090-18. PMID: 29581189
Biomed Res Int

In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]

2018 Jul 2:2018:3579832. PMID: 30065936
University of Texas

2025.
bioRxiv

2024 May 10.
Chemosphere

Insights into the degradation mechanisms and pathways of cephalexin during homogeneous and heterogeneous photo-Fenton processes. [Abstract]

2021 Dec:285:131417. PMID: 34246101
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Jawad A M, et al. Innovation, preparation of cephalexin drug derivatives and studying of (toxicity & resistance of infection)[J]. International Journal of Psychosocial Rehabilitation, 2020, 24(04): 3754-3767.

[2]. Benarab N, et al. The issues of antibiotics: cephalexin antibiotic as emerging environment contaminant[J]. Int. J. Sci. Res. Publ, 2020, 10(2): 306-318.

[3]. Wick WE. Cephalexin, a new orally absorbed cephalosporin antibiotic. Applied microbiology. 1967 Jul;15(4):765-9. [Content Brief]

[4]. Lode H, et al. Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrobial agents and chemotherapy. 1979 Jul;16(1):1-6. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Cephalexin sodium

9 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- 体外実験
- 体内実験
化学情報
Publications (9)
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Cephalexin sodium

MedChemExpress（MCE）の使用を引用している文献 Cephalexin sodium

Antibiotic アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (9)

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Cephalexin sodium 関連分類

HY-W747255 関連分類